Skip to content

Opening book details…

Can I read Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database on EtoBox?

Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database by Carola A. Huber; Reto Agosti; Markus Näpflin; Eva Blozik is a Medicine article available to read on EtoBox.

What is Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database about?

## Purpose: In course of the new migraine drug development on the global market it is important to quantify the current burden of migraine medication. this study aimed to estimate the comorbidity burden and its relation to healthcare costs in patients using triptans in switzerland by analyzing a large population-based database. ## Methods: This retrospective cohort study was based on swiss health insurance claims data (2015/2016). the study sample comprised adult patients with ≥1 triptan prescription in 2015. we evaluated pharmaceutically treated comorbid conditions (ccs) and costs (12 months after index prescription) of patients using triptan. multivariable linear regression models with log-transformed outcomes were performed to identify the factors related to healthcare costs. ## Results: From a total of 749 092, we identified 10,090 patients using triptans (1-year prevalence of 1.35%), whereas 58.9% had ≥2 ccs. the most frequent ccs were pain- and rheumatologic-related diseases and psychological disorders. among triptan users, the mean total healthcare costs were highest in older patients with ≥2 ccs (>64 years: migraine with ≥2 cc "12 331 sfr"). multivariate regression analyses

Who reads Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Carola A. Huber; Reto Agosti; Markus Näpflin; Eva Blozik
Published
2019
Language
EN
Field
Medicine (Health Sciences)

More by Carola A. Huber; Reto Agosti; Markus Näpflin; Eva Blozik

Browse all works by Carola A. Huber; Reto Agosti; Markus Näpflin; Eva Blozik